((自动化翻译由路透提供，请见免责声明 ))
9月18日 - ** Roivant Sciences 股价盘前上涨2.5%至12.35美元
** 医疗保健公司Organon 称， (link)，该公司已同意以12亿美元收购皮肤疗法开发商Dermavant（Roivant的子公司）。
** 该交易将使 OGN 获得 Dermavant 的银屑病药膏 VTAMA，该药膏于 2022 年 5 月获得美国 FDA 批准。
** 作为交易的一部分，OGN 将支付 1.75 亿美元的预付款以及高达 9.5 亿美元的里程碑付款
** OGN 预计在今年第四季度完成交易
** 截至上次收盘，ROIV 股价年累计上涨 7.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.